Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2023-05-09 Earnings Release
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected 2023 as a transition year in focusing on Single Pills
Earnings Release Classification · 1% confidence The document explicitly discusses financial results for the first quarter (Q1 2023), referencing 'Quarterly / Interim Statement' in the keywords, providing detailed income statements, balance sheets, and cash flow statements for the three-month period (3M 2023 vs 3M 2022). It also mentions a forecast adjustment for the fiscal year 2023. This content structure is characteristic of a comprehensive interim financial report, not just a brief earnings release (ER) or a simple announcement of a report (RPA/RNS). Since it covers a period shorter than a year (Q1), the appropriate classification is Interim / Quarterly Report (IR). The document is substantial (nearly 18,000 characters) and contains the full financial details, ruling out RPA/RNS. Q1 2023
2023-05-09 English
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights
Regulatory Filings Classification · 1% confidence The document is a news release dated May 8, 2023, originating from EQS-News, which typically disseminates corporate announcements. The content details a new development partnership between APONTIS PHARMA AG and Zentiva Group regarding a Single Pill product. This type of announcement—a strategic business development, partnership, or product pipeline update released via a news wire service—does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER) or specific corporate actions (like DIV, SHA, DIRS). Since it is a general corporate news item distributed through a regulatory news service (EQS), and it is not a formal financial report itself, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements that don't fit elsewhere.
2023-05-08 English
APONTIS PHARMA AG: Silke Reineke, buy
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a person discharging managerial responsibilities (Silke Reineke) and a person closely associated with her (Karlheinz Gast). Section 4 details the nature of the transaction ('Acquisition'), the financial instrument, price, and volume. This directly corresponds to the definition of Director's Dealing.
2023-05-05 English
APONTIS PHARMA AG adjusts forecast for fiscal year 2023
Regulatory Filings Classification · 1% confidence The document is a short announcement dated May 2, 2023, titled "APONTIS PHARMA AG adjusts forecast for fiscal year 2023." It explicitly states it is an 'Ad-hoc' announcement and discloses 'inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 (MAR)'. This type of filing, which communicates a material change in financial outlook (revenue and EBITDA forecast adjustment), is typically classified as an Earnings Release (ER) if it were the initial release of results, or a Regulatory Filing (RNS) if it's a general regulatory update. However, given the specific nature of adjusting financial guidance outside of a standard quarterly report, and the fact that it is a brief announcement (under 5,000 characters) rather than a comprehensive report, it fits best under the category for initial financial result announcements or significant updates. Since 'ER' is defined as the 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a key highlight/update regarding the annual forecast, it is the most appropriate fit among the specific financial codes. It is not a full 10-K, IR, or MDA. It is a direct regulatory disclosure of financial performance changes.
2023-05-02 English
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024
Regulatory Filings Classification · 1% confidence The document is a news release dated April 27, 2023, originating from EQS-News, which typically disseminates corporate announcements. The content focuses on a product in-licensing, planned market launch, and expected sales potential, using keywords like 'News Details', 'Corporate', and 'Product Launch'. This format strongly suggests an immediate, brief announcement of a significant business event rather than a comprehensive periodic report (like 10-K or IR) or a formal regulatory filing like a proxy statement or insider trade report. Since it is an immediate announcement of corporate news that doesn't fit perfectly into specific categories like DIV, CAP, or MANG, and it is not a transcript (CT) or a formal presentation (IP), the most appropriate classification is the general regulatory announcement/news category, RNS, as it is disseminated via a news service (EQS News) and serves as a general regulatory disclosure.
2023-04-27 English
APONTIS PHARMA: New development partnership with Midas Pharma Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential
M&A Activity Classification · 1% confidence The document is a press release dated April 12, 2023, announcing a new development partnership between APONTIS PHARMA AG and Midas Pharma regarding a Single Pill product. It details product development timelines, potential sales, and intellectual property rights. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a corporate announcement regarding business development and product pipeline expansion. Since it is a specific business update that doesn't fit the definitions for M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), it falls best under the general category of a corporate news announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general corporate news releases that are not explicitly defined elsewhere, especially since the footer mentions 'EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.' However, since the content is a specific business development announcement, and not a mandatory regulatory filing like a 10-K or a specific financial result announcement, RNS serves as the best fit among the provided codes for a general corporate news item distributed via a news service.
2023-04-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.